Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance

Whole–genome characterization of chemoresistant ovarian cancer

Ann‐Marie Patch, Elizabeth L. Christie, Dariush Etemadmoghadam et al. · Nature · 2015 · 1.6K citations

Medicine, Genetics, Oncology +14

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

Éric Pujade-Lauraine, Felix Hilpert, B. Weber et al. · Journal of Clinical Oncology · 2014 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +17

Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

Richard W. Tothill, Anna V. Tinker, Joshy George et al. · Clinical Cancer Research · 2008 · 1.5K citations

Medicine, Gynecology, Oncology +17

Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan

Alan N. Gordon, John Fleagle, David Guthrie et al. · Journal of Clinical Oncology · 2001 · 1.2K citations

Medicine, Oncology, Pharmacology +16

<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group

Kathryn Alsop, Sián Fereday, Cliff Meldrum et al. · Journal of Clinical Oncology · 2012 · 1.2K citations · Full text

Medicine, Genetics, Oncology +17